Abstract
Vagus nerve stimulation (VNS) is the most widely used non-pharmacological treatment for pharmacoresistant epilepsy since 1988 based on experimental and clinical observations over several decades. In 1997, the FDA approved VNS “as an adjunctive treatment for partial refractory epilepsy in adults and adolescents over 12 years of age”. Considering that polytherapy seldom contributes to seizure control after monotherapy has failed, the need for options—even if only palliative—to address the devastating health, psychosocial, and economic consequences of refractory epilepsy in selected groups and the increasing concern about adverse effects of medications on neurological development, VNS usage has been extended to younger age groups and patients with generalized seizures, who are not candidates for resective surgery. VNS therapy involves implantation of a battery-operated device in the upper chest with two subcutaneously placed wires with electrodes attached to the left vagus nerve in the carotid sheath. The generator is programmed by a telemetry wand attached to a laptop computer. Stimulation is usually initiated 15 days alter implantation and adjusted over time on the basis of patient tolerance and response. The safety, tolerability, and efficacy of the procedure and therapy have been repeatedly demonstrated in prospective randomized clinical trials, uncontrolled retrospective series and long-term follow-up series. Complications of surgery are rare with infection being the most often reported, while stimulation related side effects are usually mild and in most cases decrease over time or can be resolved by changing stimulation parameters. Series have shown a remarkably consistent average reduction in seizure frequency of 40–50% responder rate (i.e., the proportion of patients whose seizure frequency is reduced by at least 50%) with no obvious indication of tolerance and generally a long-term increase of efficacy. The number of patients who become seizure free is relatively small. The use of on-demand stimulation triggered by a handheld magnet that may help to prevent or abort seizures has also been cited as a substantial benefit. Other positive outcome measures include improvement in mood, alertness, memory and postictal recovery period, which have been collectively seen as improvement in quality of life. Cost-benefit of the therapy has also been documented, although in many countries the deterrent to the use of VNS is currently the initial cost of the device. However, despite extensive clinical studies and studies on experimental animal models, three aspects of VNS remain elusive (a) the exact mechanisms of action, (b) the definition of stimulation parameters for optimal seizure control, and (c) the precision of factors that can predict which patients will respond and to what extent. Given these evidences, VNS should be considered within a comprehensive epilepsy surgery center on a patient to patient basis, following a detailed bio-psycho-social workup and review of expenses ands risks weighted against expectations, and potential improvements in seizures and quality of life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aalbers M, Vles J, Klinkenberg S, Hoogland G, Majoie M, Rijkers K. Animal models for vagus nerve stimulation in epilepsy. Exp Neurol. 2011;230(2):167–75.
Air EL, Ghomri YM, Tyagi R, Grande AW, Crone K, Mangano FT. Management of vagal nerve stimulator infections: do they need to be removed? Clinical article. J Neurosurg Pediatr. 2009;3:73–8.
Aldenkamp AP, Van de Veerdonk SH, Majoie HJ, Berfelo MW, Evers SM, Kessels AG, et al. Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with Lennox-Gastaut syndrome in an open clinical and nonrandomized study. Epilepsy Behav. 2001;2(4):343–50.
Aldenkamp AP, Majoie HJ, Berfelo MW, Evers SM, Kessels AG, Renier WO, Wilmink J. Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome. Epilepsy Behav. 2002;3(5):475e9.
Alonso-Vanegas MA, Austria-Velásquez J, López Gómez M, Brust-Mascher E. Estimulación crónica intermitente del nervio vago en el tratamiento de epilepsia refractaria: experiencia en México con 35 casos. Cir Cir. 2010;78:15–24.
Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery. 2008;62 Suppl 2:506–13.
Ascanope JJ, Moore DD, Zipes DP, Hartman LM, Duffel Jr WH. Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing. Epilepsia. 1999;40:1452–4.
Barnes A, Duncan R, Chisholm JA, Lindsay K, Patterson J, Wyper D. Investigation into the mechanisms of vagus nerve stimulation for the treatment of intractable epilepsy, using 99mTc-HMPAO SPET brain images. Eur J Nucl Med Mol Imaging. 2003;30:301–5.
Bauman JA, Ridgway EB, Devinsky O, Doyle WK. Subpectoral implantation of the vagus nerve stimulator. Neurosurgery. 2006;58 ONS:322–5.
Benifla M, Rutka JT, Logan W, Donner EJ. Vagal nerve stimulation for refractory epilepsy in children: indications and experience at The Hospital for Sick Children. Childs Nerv Syst. 2006;22:1018–26.
Ben-Menachem E. Vagus nerve stimulation, side effects and long-term safety. J Clin Neurophysiol. 2001;18:415–8.
Ben-Menachem E, Hellström K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology. 2002;59 Suppl 4:S44–7.
Bernstein AL, Barkan H, Hess T. Vagus nervestimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav. 2007;10:134–7.
Biggio F, Gorini G, Utzeri C, Olla P, Marrosu F, Mocchetti I, et al. Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. Int J Neuropsychopharmacol. 2009;12:1209–21.
Boon P, Vonck K, Van Walleghem P, D'Havé M, Goossens L, Vandekerckhove T, et al. Programmed and magnet-induced vagus nerve stimulation for refractory epilepsy. J Clin Neurophysiol. 2001;18:402–7.
Boon P, D'Havé M, Van Walleghem P, Michielsen G, Vonck K, Caemaert J, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia. 2002;43:96–102.
Chawla J, Suscholeiki R, Jones C, Silver K. Intractable epilepsy with ring chromosome 20 syndrome treated with vagal nerve stimulation: case report and review of the literature. J Child Neurol. 2002;17:778–80.
Connor Jr DE, Nixon M, Nanda A, Guthikonda B. Vagal nerve stimulation for the treatment of medically refractory epilepsy: a review of the current literature. Neurosurg Focus. 2012;32(3):E12.
De Herdt V, Boon P, Ceulemans B, Hauman H, Lagae L, Legros B, et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol. 2007;11:261–9.
de Vos CC, Melching L, van Schoonhoven J, Ardesch JJ, de Weerd AW, van Lambalgen HC, et al. Predicting success of vagus nerve stimulation (VNS) from interictal EEG. Seizure. 2011;20(7):541–5.
Dedeurwaerdere S, Vonck K, Van Hese P, Wadman W, Boon P. The acute and chronic effect of vagus nerve stimulation in genetic absence epilepsy rats from Strasbourg (GAERS). Epilepsia. 2005;46 Suppl 5:94–7.
Dedeurwaerdere S, Gilby K, Vonck K, Delbeke J, Boon P, McIntyre D. Vagus nerve stimulation does not affect spatial memory in fast rats, but has both anti-convulsive and pro-convulsive effects on amygdala-kindled seizures. Neuroscience. 2006;140:1443–51.
Dodrill CB, Morris GL. Effects of vagal nerve stimulation on cognition and quality of life in epilepsy. Epilepsy Behav. 2001;2(1):46–53.
Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res. 2000;42(2–3):203–10.
Elliott RE, Morsi A, Kalhorn SP, Marcus J, Sellin J, Kang M, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsia. 2011a;20:57–63.
Elliott RE, Rodgers SD, Bassani L, Morsi A, Geller EB, Carlson C, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr. 2011b;7:491–500.
Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. 2011;115(6):1248–55.
FDA. VNS therapy system for adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older. FDA approvals, 2005. 2005. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078532.htm. Accessed on 12 Sept 2011.
Fernandez-Guardiola A, Martinez A, Valdes-Cruz A, Magdaleno-Madrigal VM, Martinez D, Fernandez-Mas R. Vagus nerve prolonged stimulation in cats: effects on epileptogenesis (amygdala electrical kindling): behavioral and electro-graphic changes. Epilepsia. 1999;40:822–9.
Follesa P, Gale K, Mocchetti I. Regional and temporal pattern expression of nerve growth factor and basic fibroblast growth factor mRNA in rat brain following electroconvulsive shock. Exp Neurol. 1994;127:37–44.
Frost M, Gates J, Helmers SL, Wheless JW, Levisohn P, Tardo C, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia. 2001;42:1148–52.
Hallbook T, Lundgren J, Kohler S, Blennow G, Strömblad LG, Rosén I. Beneficial effects on sleep of vagus nerve stimulation in children with therapy resistant epilepsy. Eur J Paediatr Neurol. 2005;9(6):399–407.
Hammond E, Uthmann B, Reid S, Wilder B. Electrophysiological studies of cervical vagus nerve stimulation in humans. I. EEG effects. Epilepsia. 1992;33:1013–20.
Helmers SL, Duh MS, Guérin A, Sarda SP, Samuelson TM, Bunker MT, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav. 2011;22(2):370–5.
Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. No evidence for cognitive side effects after 6 months of vagus nerve stimulation in epilepsy patients. Epilepsy Behav. 2001;2(4):351–6.
Hornig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J. 1997;90:484–8.
Hosoi T, Okuma Y, Nomura Y. Electrical stimulation of afferent vagus nerve induces IL-1beta expression in the brain and activates HPA axis. Am J Physiol Regul Integr Comp Physiol. 2000;279:R141–7.
Janszky J, Hoppe M, Behne F, Tuxhorn I, Pannek HW, Ebner A. Vagus nerve stimulation: predictors of seizure freedom. J Neurol Neurosurg Psychiatry. 2005;76:384–9.
Klinkenberg S, Aalbers MW, Vles JS, Cornips EM, Rijkers K, Leenen L, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol. 2012a;54(9):855–61.
Klinkenberg S, Majoie HJM, van der Heijden MMAA, Rijkers K, Leenen L, Aldenkamp AP. Vagus nerve stimulation has a positive effect on mood in patients with refractory epilepsy. Clin Neurol Neurosurg. 2012b;114:336–40.
Klinkenberg S, van den Bosch CN, Majoie HJ, Aalbers MW, Leenen L, Hendriksen J, Cornips EMJ, Rijkers K, Vles JS, Aldenkamp AP. Behavioural and cognitive effects during vagus nerve stimulation in children with intractable epilepsy – A randomized controlled trial. Eur J Paediatr Neurol. 2013;17(1):82–90.
Koo B. EEG changes with vagus nerve stimulation. J Clin Neurophysiol. 2001;18:434–41.
Krahl S, Senanayake S, Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression in rats. Epilepsia. 2001;42:586–9.
Kuba R, Guzaninova M, Brazdil M, Novak Z, Chrastina J, Rektor I. Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp EEG study. Epilepsia. 2002;43(10):1181–8.
Kuba R, Brazdil M, Novak Z, Chrastina J, Rector I. Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur J Neurol. 2003;10:91–4.
Kulkarni VA, Jha S, Vaidya VA. Depletion of norepinephrine decreases the proliferation, but does not influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus. Eur J Neurosci. 2002;16:2008–12.
Labar D, Ponticello L. Persistent antiepileptic effects after vagus nerve stimulation ends? Neurology. 2003;61:1818.
Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group. Neurology. 1999;52:1510–2.
Lockard JS, Congdon WC, DuCharme LL. Feasibility and safety of vagal nerve stimulation in monkey model. Epilepsia. 1990;31:20–6.
Magdaleno-Madrigal V, Valdes-Cruz A, Martinez-Vargas D, Almazan-Alvarado S, Fernandez-Mas R, Fernandez-Guardiola A. Effect of vagus nerve stimulation on later stages of amygdaloid kindling in freely-moving cats. FENS Abstr. 2004;2:A124.118.
Majkowska-Zwolińska B, Zwoliński P, Roszkowski M, Drabik K. Long-term results of vagus nerve stimulation in children and adolescents with drug-resistant epilepsy. Childs Nerv Syst. 2012;28:621–8.
Marrosu F, Serra A, Maleci A, Puligheddu M, Biggio G, Piga M. Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res. 2003;55(1–2):59–70.
Marrosu F, Santoni F, Puligheddu M, Barberini L, Maleci A, Ennas F, et al. Increase in 20–50 Hz (gamma frequencies) power spectrum and synchronization after chronic vagal nerve stimulation. Clin Neurophysiol. 2005;116:2026–36.
McGlone J, Valdivia I, Penner M, Williams J, Sadler RM, Clarke DB. Quality of life and memory after vagus nerve stimulator implantation for epilepsy. Can J Neurol Sci. 2008;35(3):287–96.
McLachlan RS, Sadler M, Pillay N, Guberman A, Jones M, Wiebe S, et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor? Eur Neurol. 2003;50(1):16–9.
Meurs A, Clinckers R, Raedt R, El Tahry R, De Herdt V, Vonck K, et al. Vagus nerve stimulation suppressess pilocarpine- induced limbic seizures and increases hippocampal extracellular noradrenalin concentration. Epilepsia. 2008;49:350.
Morris III GL. A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy. Epilepsy Behav. 2003;4:740–5.
Muñana KR, Vitek SM, Tarver WB, Saito M, Skeen TM, Sharp NJ, et al. Use of vagal nerve stimulation as a treatment for refractory epilepsy in dogs. J Am Vet Med Assoc. 2002;221:977–83.
Murphy JV, Wheeles JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. Pediatr Neurol. 2000;23:167–8.
Murphy JV, Torkelson R, Dowler I, Simon S, Hudson S. Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center. Arch Pediatr Adolesc Med. 2003;157:560–4.
Narayanan JT, Watts R, Hadad N, Labar DR, Li PM, Filippi CG. Cerebral activation during vagus nerve stimulation: a functional MR study. Epilepsia. 2002;43:1509–14.
Naritoku D, Mikels JA. Vagus nerve stimulation (VNS) is antiepileptogenic in the electrical kindling model. Epilepsia. 1997;38:220.
Neese SL, Sherill LK, Tan AA, Roosevely RW, Browning RA, Smith DC, et al. Vagus nerve stimulation may protect GABAergic neurons following traumatic brain injury in rats: an immunocytochemical study. Brain Res. 2007;1128(1):157–63.
Parain D, Penniello MJ, Berquen P, Delangre T, Billard C, Murphy JV. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol. 2001;25:213–6.
Patwardhan RV, Stong B, Bebin EM, Mathisen J, Grabb PA. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery. 2000;47:1353–7.
Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun. 2005;19:493–9.
Revesz D, Tjernstrom M, Ben-Menachem E, Thorlin T. Effects of vagus nerve stimulation on rat hippocampal progenitor proliferation. Exp Neurol. 2008;214:259–65.
Rijkers K, Aalbers M, Hoogland G, van Winden L, Vles J, Steinbusch H, et al. Acute seizure-suppressing effect of vagus nerve stimulation in the amygdala kindled rat. Brain Res. 2010;1319:155–63.
Ring HA, White S, Costa DC, Pottinger R, Dick JP, Koeze T, et al. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy. Seizure. 2000;9:380–4.
Schachter SC, Wheless JW (eds). Vagus nerve stimulation therapy 5 years after approval: a comprehensive update. Neurology. 2002;59 Suppl 4:S1–61.
Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: more to VNS than seizure frequency reduction. Epilepsia. 2009;50:1220–8.
Takaya M, Terry W, Naritoku D. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia. 1996;37:1111–6.
The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology. 1995;45:224–30.
Thompson EM, Wozniak SE, Roberts CM, Kao A, Anderson VC, Selden NR. Vagus nerve stimulation for partial and generalized epilepsy from infancy to adolescence. J Neurosurg Pediatr. 2012;10(3):200–5.
Vale FL, Ahmadian A, Youssef AS, Tatum WO, Benbadis SR. Long-term outcome of vagus nerve stimulation therapy after failed epilepsy surgery. Seizure. 2011;20(3):244–8.
Vonck K, Thadani V, Gilbert K, Dedeurwaerdere S, De Groote L, De Herdt V, et al. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. J Clin Neurophysiol. 2004;21:283–9.
Walker BR, Easton A, Gale K. Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Epilepsia. 1999;40:1051–7.
Wheless JW, Maggio V. Vagus nerve stimulation therapy in patients younger than 18 years. Neurology. 2002;59 Suppl 4:S21–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Alonso-Vanegas, M.A. (2013). Vagus Nerve Stimulation for Intractable Seizures. In: Rocha, L., Cavalheiro, E. (eds) Pharmacoresistance in Epilepsy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6464-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6464-8_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6463-1
Online ISBN: 978-1-4614-6464-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)